Value-Based Cancer Care Issues

June 2010, Vol 1, No 2

From Dollars to Sense

Comparative Effectiveness

With the inclusion of $1.1 billion in the American Recovery and Reinvest ment Act of 2009 for comparative effectiveness research (CER), this topic has suddenly become a matter of great importance in the clinical and research communities. The idea of [ Read More ]

CER: Use, Controversy Both Growing

VBCC Perspectives

Even before enactment of national healthcare reform initiatives, development and implementation of a variety of comparative effectiveness research (CER) was well under way, even if it was not specifically called comparative effectiveness. Humana’s recent Medical Coverage Policy for taxanes, for [ Read More ]

$3 Million to Toss a Life Ring?

AACR Annual Meeting

Washington, DC—Three million dollars to toss a life ring? That’s what the pharmaceutical industry would charge, the director of Medical Ethics at Harvard’s School of Medicine suggested at the 101st Annual Meeting of the American Association for Cancer Research (AACR), [ Read More ]

Oncology-related Updates from the US Food and Drug Administration


IV Ondansetron May Be Contaminated The FDA has alerted healthcare professionals not to use certain intravenous (IV) bags of ondansetron (an antiemetic) and metronidazole and ciprofloxacin (both antibiotics) because of potential contamination. IV bags manufactured by Claris Life – sciences [ Read More ]